ニュース

Find insight on the deal between Hengrui Pharmaceuticals and Bristol Myers Squibb and more in the latest Market Talks covering the health care sector.

U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.

U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q